Literature DB >> 21537122

Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance.

Leonardo Marzio1, Lugina Cellini, Maria Amitrano, Rossella Grande, Mariaelena Serio, Giorgio Cappello, Laurino Grossi.   

Abstract

INTRODUCTION: The treatment failure of Helicobacter pylori (H. pylori) infection may be mainly because of antibiotic resistance and the presence of a mixed infection in the same patient. AIM: To investigate the incidence of mixed infection and discordant antibiotic resistance in patients never treated and already treated.
MATERIALS AND METHODS: Susceptibility test to amoxicillin, rifabutin, tinidazole, clarithromycin, levofloxacin, and moxifloxacin was conducted on H. pylori strains culture from 76 patients never treated and 72 patients already treated unsuccessfully. DNA fingerprinting was determined on H. pylori strains harboring in the same patient with a discordant resistance to the same antibiotic.
RESULTS: Forty percent of patients never treated and 53% of patients already treated showed a pangastric infection. The overall resistance to amoxicillin, clarithromycin, and tinidazole was significantly higher in patients with pangastric infection in comparison with those with the infection in the antrum (P<0.05). Discordant resistance was present in 33% of patients never treated, and 21% of patients already treated. DNA fingerprinting showed substantial differences among DNA patterns suggesting a mixed infection.
CONCLUSION: Culture and susceptibility test should be performed when necessary not only in the antrum but also in the fundus of patients with H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537122     DOI: 10.1097/MEG.0b013e328345d40f

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection.

Authors:  Michael Selgrad; Ina Tammer; Cosima Langner; Jan Bornschein; Julia Meißle; Arne Kandulski; Mariya Varbanova; Thomas Wex; Dirk Schlüter; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 2.  Helicobacter pylori culture: from bench to bedside.

Authors:  Angelo Zullo; Vincenzo De Francesco; Luigi Gatta
Journal:  Ann Gastroenterol       Date:  2022-03-25

3.  Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes.

Authors:  Masoud Alebouyeh; Abbas Yadegar; Nastaran Farzi; Marzyieh Miri; Homayoon Zojaji; Somayeh Gharibi; Zeinab Fazeli; Naser Ebrahimi Daryani; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

Review 4.  Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review.

Authors:  Javier P Gisbert
Journal:  Pathogens       Date:  2020-12-28

5.  Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China.

Authors:  Mengheng Mi; Fangcao Wu; Jian Zhu; Fang Liu; Guzhen Cui; Xueqing Wen; Yue Hu; Zhaohui Deng; Xiaojuan Wu; Zhengrong Zhang; Tingna Qi; Zhenghong Chen
Journal:  Infect Drug Resist       Date:  2021-02-11       Impact factor: 4.003

Review 6.  Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis.

Authors:  Ebrahim Kouhsari; Nourkhoda Sadeghifard; Arezoo Khadiv; Hojjat Sayadi; Taghi Amiriani; Sobhan Ghafourian; Hassan Valadbeigi; Marcela Krutova
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-05-20       Impact factor: 3.944

7.  Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study.

Authors:  Antonio Francesco Ciccaglione; Mara Di Giulio; Silvia Di Lodovico; Emanuela Di Campli; Luigina Cellini; Leonardo Marzio
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

8.  Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study.

Authors:  Jewel Ju Ea Kim; Ildikó Kocsmár; György Miklós Buzás; Ildikó Szirtes; Orsolya Rusz; Csaba Diczházi; Attila Szijártó; István Hritz; Zsuzsa Schaff; András Kiss; Éva Kocsmár; Gábor Lotz
Journal:  Pathol Oncol Res       Date:  2021-06-29       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.